On April 15, 2026 Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, reported it will participate in RedChip’s upcoming virtual investor conference, "Biotech Resurgence: Platforms and Pipelines of Today’s Innovators," taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. E.T.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The full-day event will spotlight publicly traded companies advancing innovation across biotechnology, therapeutics, medical devices, diagnostics, and digital health. The conference will provide investors with direct access to executive leadership teams developing next-generation healthcare platforms, advancing clinical pipelines, and scaling commercial healthcare solutions.
Registration is free and open to the public: View Source
RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist (IL-15 SA), a known T and NK-cell activator, in the TME. The Company expects to file an IND for CLD-401 by the end of 2026. Additionally, Calidi is expanding the RedTail platform to enable in situ expression of T-cell engagers (TCEs) in solid tumors, including in combination with T-cell activating payloads such as IL15 SA. This strategy is intended to support localized T-cell engagement within the TME following systemic administration. The Company is developing CLD-501, a RedTail virus that expresses high levels of a TROP2-targeting TCE and IL-15SA in the TME.
"I look forward to discussing the advances we’ve made with the RedTail platform and the path to IND filing expected this year for CLD-401" said Eric Poma, PhD, Chief Executive Officer of Calidi. "We continue to expand what the RedTail platform can do with new payload, a novel approach to in situ T-cell engagers, and ongoing lead discovery in indications outside of oncology."
The Company continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.
(Press release, Calidi Biotherapeutics, APR 15, 2026, View Source [SID1234664424])